3178-39-0

Upstream product

• 162739-86-8 tert-butyl 2-(2-phenylpropan-2-yl)hydrazinecarboxylate 
• 98-82-8 Isopropylbenzene 
• 58654-22-1 acetone-(1-methyl-1-phenyl-ethylhydrazone) 
• 64728-42-3 diethyl 1-(1-phenyl-1-methylethyl)-1,2-hydrazinedicarboxylate 

Downstream Products

• 1380230-60-3 methyl 2-(5-oxo-1-(2-phenylpropan-2-yl)-4,5-dihydro-1H-pyrazol-3-yl)acetate 
• 1380230-58-9 3-(2-methyl-1-phenylpropan-2-yl)-1-(2-phenylpropan-2-yl)-1H-pyrazol-5(4H)-one 
• 25683-96-9 Cyclohexan-α-cumylhydrazin 
• 25683-97-0 2-phenyl-2-(1-piperidinyl)propane 
• 25683-93-6 α-Cumylazo-cyclohexan 
• 60104-03-2 3-(1-methyl-1-phenyl-ethyl)-[1,3,4]oxadiazolidine-2,5-dione 
• 60103-97-1 N'-chlorocarbonyl-N'-(1-methyl-1-phenyl-ethyl)-hydrazinecarboxylic acid benzyl ester 
• 60104-00-9 5-benzyloxy-3-(1-methyl-1-phenyl-ethyl)-3H-[1,3,4]oxadiazol-2-one 
• 25683-95-8 Cyclohexanon-α-cumylhydrazon 

Relevant academic research and scientific papers

PYRAZOLE COMPOUNDS HAVING THERAPEUTIC EFFECT ON MULTIPLE MYELOMA

Novel therapeutic agents for myeloma are provided. A therapeutic agent for multiple myeloma containing a pyrazole compound represented by the formula (1): wherein R1 is C1-C6 alkyl, C1-C6 alkyl substituted with R17, C1-C6 haloalkyl, phenyl, phenyl substituted with a R11's or the like, R2 is a hydrogen atom, C1-C6 alkyl, phenyl or phenyl optionally substituted with e R21's or the like, R3 is a hydrogen atom or the like, X is a single bond or —(CR6, R7)n—, each of R4 and R5 is independently C1-C6 alkyl or the like, R6 and R7 are hydrogen atoms or C1-C6 alkyl, R8 is phenyl, phenyl optionally substituted with k R81's or the like, a tautomer of the compound or a pharmaceutically acceptable salt or solvate thereof, as an active ingredient.